Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Gerlinde Wernig, MD, Michael G. Kharas, PhD, Rachel Okabe, Sandra A. Moore, Dena S. Leeman, Dana E. Cullen, Maricel Gozo, Elizabeth P. McDowell, Ross L. Levine, John Doukas, Chi Ching Mak, Glenn Noronha, Michael Martin, Yon D. Ko, Benjamin H. Lee, Richard Soll, Ayalew Tefferi, John D. Hood, D. Gary Gilliland

Blood (2007) 110 (11): 556.

https://doi.org/10.1182/blood.V110.11.556.556

Published: 2007

Journal Articles

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

Terra L. Lasho, MT, Christy Finke, John D. Hood, PhD, Richard Soll, PhD, Glenn Noronha, PhD, Ruben A. Mesa, MD, Catriona Jamieson, MD, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Hagop Kantarjian, MD, D. Gary Gilliland, MD, PhD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD

Blood (2007) 110 (11): 3541.

https://doi.org/10.1182/blood.V110.11.3541.3541

Published: 2007

Journal Articles

TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.

Betty Tam, PhD, Chi Ching Mak, Ph.D., Silva Stoughton, B.Sc., Cyrus Virata, B.Sc., Dan Lohse, Ph.D., Ehab Hanna, M.Sc., Marcela Alomia, B.Sc, Catriona Jamieson, MD., Ph.D., John Doukas, Ph.D., Glenn Noronha, Ph.D., Michael Martin, Ph.D., Richard Soll, Ph.D., John Hood, Ph.D.

Blood (2007) 110 (11): 898.

https://doi.org/10.1182/blood.V110.11.898.898

Published: 2007

Journal Articles

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Animesh Pardanani, MD, PhD, John Hood, PhD, Terra Lasho, Glenn Noronha, PhD, Christy Finke, Chi Ching Mak, PhD, Ruben Mesa, MD, Hong Zhu, PhD, Richard Soll, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2680.

https://doi.org/10.1182/blood.V108.11.2680.2680

Published: 2006

Journal Articles

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

Ifat Geron, MS, Charlene Barroga, PhD, Jason Gotlib, MD MS, Edward Kavalerchik, MD, Annelie Abrahamsson, MS, Daniel Goff, BS, Nicholas Cacalano, PhD, John Hood, PhD, Richard Soll, MD, Glenn Noronha, PhD, Ayalew Tefferi, MD, Irving L. Weissman, MD, Kenneth Kaushansky, MD PhD, Catriona Jamieson, MD, PhD

Blood (2006) 108 (11): 3616.

https://doi.org/10.1182/blood.V108.11.3616.3616

Published: 2006

Journal Articles

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

John Hood, PhD, Jon Cao, PhD, Ehab Hanna, MS, Dan Lohse, PhD, Chi Ching Mak, PhD, Andrew McPherson, PhD, Glenn Noronha, PhD, Joel Renick, MS, Binqi Zheng, PhD, Hong Zhu, PhD, Richard Soll, PhD

Blood (2006) 108 (11): 3632.

https://doi.org/10.1182/blood.V108.11.3632.3632

Published: 2006

Journal Articles

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

Hong Zhu, PhD, Ehab Hanna, M.S., Dan Lohse, Ph.D., Silva Stoughton, B.S., Betty Tam, Ph.D., Kathy Barrett, M.S., Glenn Noronha, Ph.D., Elena Dneprovskaia, Ph.D., Jon Cao, Ph.D., Chun Chow, Ph.D., Linda Hwang, B.S., Chiching Mak, Ph.D., Andy McPherson, Ph.D., Moorthy Palanki, Ph.D., Ved P. Pathak, Ph.D., Joe Renick, M.S., Richard Soll, Ph.D., Binqi Zeng, Ph.D., John Hood, Ph.D.

Blood (2006) 108 (11): 2182.

https://doi.org/10.1182/blood.V108.11.2182.2182

Published: 2006

NARROW

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

Email alerts

ASH Publications

American Society of Hematology

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera.

Primary Cell Experiments with TG101348, a JAK2-Selective Inhibitor, in the Presence of Myeloproliferative Disorder-Associated JAK2V617F, MPLW515L/K, and JAK2 Exon 12 Mutations.

TG101348: A Dual-Acting JAK2/FLT3 Small Molecule Kinase Inhibitor for the Treatment of AML.

TG101209, a Selective JAK2 Kinase Inhibitor, Suppresses Endogenous and Cytokine-Supported Colony Formation from Hematopoietic Progenitors Carrying JAK2 V617F or MPL W515K/L Mutations.

Inhibition of JAK2 V617F-Induced Erythroid Skewing of Hematopoietic Stem Cell Differentiation with a Selective JAK2 Antagonist.

JAK2 Inhibitors for the Treatment of Myeloprolifertive Disorders.

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only